Table 4. Alterations detected in Rectal cancer (RC) patients (n=25).
| Patient | SNV | Allele Frequency |
Validation (Sequencing) | CNA | Validation (RT-PCR) | Fusion |
|---|---|---|---|---|---|---|
| RC1 | ND | NGS Panel** | ||||
| RC2 | ND | NGS Panel** | FGFR1 (7.5) | Yes | ||
| RC3 | ND | |||||
| RC4 | ND | |||||
| RC5 | ND | |||||
| RC6 | BRAF-V600E | 10% | Sanger | |||
| RC7 | KRAS-A146P | 16% | ||||
| RC8 | KRAS-G12V | 41% | Sanger | |||
| RC9 | ND | |||||
| RC10 | ND | |||||
| RC11 | ND | |||||
| RC12 | ND | |||||
| RC13 | KRAS-A146T ERBB2-S310F |
47% 40% |
||||
| RC14 | KRAS-G13D | 15.5% | Sanger | |||
| RC15 | ND | |||||
| RC16 | ND | |||||
| RC17 | ND | |||||
| RC18 | KRAS-G12V PIK3CA-E545K EGFR-A289D |
27% 19% 6% |
Sanger Sanger * |
|||
| RC19 | KRAS-G13D AKT1-E17K |
23% 13% |
||||
| RC2 | ND | |||||
| RC21 | ND | |||||
| RC22 | KRAS-G12V | 38% | ||||
| RC23 | ND | |||||
| RC24 | KRAS-G12S PIK3CA-E545K |
24% 12% |
Sanger Sanger |
|||
| RC25 | ND |
* SNV not confirmed by Sanger sequencing.
** The NGS Panel used is the Comprehensive Cancer Panel from Thermofisher.